CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $946.54M, above the global median of $558.46M
- PositionCurrent ratio is 0.88×, lower than 95% of its Biotechnology peers (median 5.96×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
743.76BKRW536.84M · vs all stocks (USD)
Revenue (TTM)
1.31TKRW946.54M · vs all stocks (USD)
Profit Margin
1.09%vs Biotechnology peers
Beta
0.5920xvs all stocks
52-Week Change
-27.99%vs all stocks
Market Capitalization
743.76BKRW536.84M · vs all stocks (USD)
Enterprise Value
1.78TKRW1.29B · vs all stocks (USD)
Price to Sales (TTM)
0.5672xvs Biotechnology peers
Price to Book (MRQ)
0.7207xvs Biotechnology peers
Enterprise to Revenue
1.36xvs Biotechnology peers
Enterprise to EBITDA
-70.50xvs Biotechnology peers
Gross Margin
27.44%vs Biotechnology peers
Profit Margin
1.09%vs Biotechnology peers
Operating Margin
-8.91%vs Biotechnology peers
Return on Assets (TTM)
-2.01%vs Biotechnology peers
Return on Equity (TTM)
-1.80%vs Biotechnology peers
Revenue (TTM)
1.31TKRW946.54M · vs all stocks (USD)
Revenue per Share (TTM)
15.75KKRWUpdated Sep 19, 2026Quarterly Revenue Growth
5.90%vs Biotechnology peers
Gross Profit (TTM)
362.13BKRW261.39M · vs all stocks (USD)
EBITDA (TTM)
101.78BKRW73.46M · vs all stocks (USD)
Net Income (TTM)
14.27BKRW10.30M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
5.87%vs Biotechnology peers
Operating Cash Flow (TTM)
-100.52BKRW-72.55M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-247.91BKRW-178.94M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
504.64BKRWFY2025 · Dec 31, 2025Revenue
1.27TKRWFY2025 · Dec 31, 2025Cost of Goods Sold
904.50BKRWFY2025 · Dec 31, 2025Gross Profit
363.75BKRWFY2025 · Dec 31, 2025Operating Income
-48.44BKRW-34.97M · vs all stocks (USD)
Pre-tax Income
-143.26BKRWFY2025 · Dec 31, 2025Income Tax Expense
3.45BKRWFY2025 · Dec 31, 2025Net Income
-146.71BKRWFY2025 · Dec 31, 2025EBIT
-88.42BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
4.93BKRWFY2025 · Dec 31, 2025Research & Development
24.59BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
184.46BKRWFY2025 · Dec 31, 2025Other Operating Expenses
26.63BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
11.46BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
54.85BKRWFY2025 · Dec 31, 2025EPS (Basic)
-1.64KKRWFY2025 · Dec 31, 2025EPS (Diluted)
-1.65KKRWFY2025 · Dec 31, 2025Basic Shares Outstanding
67.12MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
67.12MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-146.71BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
36.83BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-142.06BKRWFY2025 · Dec 31, 2025Free Cash Flow
-242.59BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
237.56BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-146.71BKRWFY2025 · Dec 31, 2025Stock-based Compensation
201.48MKRWFY2025 · Dec 31, 2025Other Non-cash Items
52.16BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.29BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-37.42BKRWFY2025 · Dec 31, 2025Capital Expenditures
-100.53BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-4.71BKRWFY2025 · Dec 31, 2025Net Acquisitions
-75.79BKRWFY2025 · Dec 31, 2025Purchase of Investments
-162.74BKRWFY2025 · Dec 31, 2025Sale of Investments
229.64BKRWFY2025 · Dec 31, 2025Other Investing Activity
-26.27BKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-135.69BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
104.70BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-84.56BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-10.39BKRWFY2025 · Dec 31, 2025Other Financing Charges
-1.72BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
189.75BKRWFY2025 · Dec 31, 2025Shares Outstanding
92.97MSharesUpdated Sep 19, 2026Float Shares
72.88MSharesUpdated Sep 19, 2026% Held by Insiders
24.64%vs all stocks
% Held by Institutions
8.72%vs all stocks
Total Cash (MRQ)
364.24BKRW262.91M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.94KKRWUpdated Sep 19, 2026Total Debt (MRQ)
815.35BKRW588.52M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.7934xvs Biotechnology peers
Current Ratio (MRQ)
0.8790xvs Biotechnology peers
Book Value per Share (MRQ)
11.10KKRWUpdated Sep 19, 2026Total Assets
2.55TKRW1.84B · vs all stocks (USD)
Total Current Assets
888.14BKRWFY2025 · Dec 31, 2025Total Liabilities
1.74TKRWFY2025 · Dec 31, 2025Total Non-current Assets
1.66TKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
415.14BKRWFY2025 · Dec 31, 2025Total Current Liabilities
1.32TKRWFY2025 · Dec 31, 2025Cash Equivalents
237.56BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
237.56BKRWFY2025 · Dec 31, 2025Other Short-term Investments
101.67BKRWFY2025 · Dec 31, 2025Accounts Receivable
134.96BKRWFY2025 · Dec 31, 2025Inventory
59.60BKRWFY2025 · Dec 31, 2025Accounts Payable
57.59BKRWFY2025 · Dec 31, 2025Short-term Debt
680.91BKRWFY2025 · Dec 31, 2025Other Current Liabilities
19.97BKRWFY2025 · Dec 31, 2025Long-term Debt
224.52BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
9.66BKRWFY2025 · Dec 31, 2025Common Stock (Book)
39.65BKRWFY2025 · Dec 31, 2025Retained Earnings
164.80BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
809.25BKRW584.12M · vs all stocks (USD)
Treasury Stock
3.58BKRWFY2025 · Dec 31, 202552-Week Low
7.60KKRWUpdated Sep 19, 202652-Week High
23.95KKRWUpdated Sep 19, 202652-Week Change
-27.99%vs all stocks
Beta
0.5920xvs all stocks
50-Day MA
8.71KKRWUpdated Sep 19, 2026200-Day MA
14.39KKRWUpdated Sep 19, 2026Avg 10-Day Volume
202.64KSharesUpdated Sep 19, 2026Avg 30-Day Volume
301.19KSharesUpdated Sep 19, 2026Diluted EPS (TTM)
-1.65KKRWUpdated Sep 19, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Working Capital Pattern
What customers owe has grown three years running, while it clears stock quickly and pays suppliers quickly.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.88×, lower than 95% of its Biotechnology peers (median 5.96×)Significant
Current ratio: 0.88Industry median: 5.96Industry P5: 1.06Peers compared: 258
Price-to-book is 0.72×, lower than 95% of its Biotechnology peers (median 2.91×)Notable
Price-to-book: 0.72Industry median: 2.91Industry P5: 0.99Peers compared: 258
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 10,301,875.51Operating Cash Flow (USD, TTM): -72,552,587.57
Financial Health
Altman Z-Score 0.53: distress zoneCritical
Altman Z-Score: 0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $946.54M, above the global median of $558.46MNotable
Revenue (USD): 946,535,029.958Global Median: 558,459,881.051
Companies that share the same coordination system — how they create, deliver, or capture value.
Kingchem Liaoning Life Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BrainsWay Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pulike Biological Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shen Lian Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pharmicell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Orchid Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Delcath Systems Inc.
Tier 1ProductionApproval-Gated PipelineRule
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Wuhan Easydiagnosis Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Tegma Gestão Logística S.A.
3 interpretationsIndustry-Benchmarked Return on Capital ElevatedWorking Capital PatternRevenue Growing With Receivables Growing
Triple Flag Precious Metals Corp
3 interpretationsIndustry-Benchmarked Return on Capital ElevatedWorking Capital PatternRevenue Growing With Receivables Growing
Digital Information Technologies Corporation
3 interpretationsIndustry-Benchmarked Return on Capital ElevatedWorking Capital PatternRevenue Growing With Receivables Growing